Drug Profile
Tirbanibulin - Almirall/Athenex
Alternative Names: ALM-14789; KLISYRI; Klisyri; KX-01; KX-2391Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Kinex Pharmaceuticals
- Developer Almirall S.A.; Athenex; Hanmi Pharmaceutical; Kinex Pharmaceuticals; PharmaEssentia Corporation
- Class Acetamides; Antineoplastics; Antipsoriatics; Morpholines; Phenyl ethers; Pyridines; Skin disorder therapies; Small molecules
- Mechanism of Action Src-Family kinase inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Actinic keratosis
- Phase II Psoriasis
- Phase I/II Solid tumours
- No development reported Acute myeloid leukaemia; Photodamage; Prostate cancer; Skin cancer
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for preclinical development in Skin-cancer in USA (PO)
- 19 Feb 2024 Almirall plans to file an application for label expansion of tirbanibulin to large field in Europe in 2026
- 21 Nov 2023 Almirall plans a phase III trial in Actinic keratosis [Topical,Ointment] in December 2023 (NCT06135415)